Physician profile
Scott Cunningham
NPI 1568403624
$8,085.66
in general payments reported to CMS, 2019-2025
20 companies · $2,693 in 2025
The $2,693 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $283 · 2021: $304 · 2022: $940 · 2023: $1,356 · 2024: $1,958 · 2025: $2,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,995 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,994.88 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,540.78 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $897.78 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $879.48 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $700.75 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $653.54 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $615.25 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $509.36 | 2021-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $486.37 | 2020-2025 | Rexulti |
| Axsome Therapeutics, INC. | $456.16 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $399.93 | 2019-2025 | Ingrezza |
| Indivior INC. | $185.13 | 2022-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $184.46 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $144.83 | 2019-2021 | |
| Allergan, INC. | $101.05 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.83 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $83.23 | 2022-2025 | Trintellix |
| Corium, LLC | $57.54 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $44.58 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $41.30 | 2022 | |
| Merck Sharp & Dohme LLC | $15.31 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.